VEGFA and neoplasm: This difference could make a significant difference to tumor therapy as it is still under debate whether blood vessel normalization by anti-VEGF agents is beneficial for patients, e.g. by supporting delivery of standard-of-care drugs or is detrimental by supporting tumor growth [35].